Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Xiaojing Zhong, Tongtong Xu, Tianhao Li, Nana Luo, Nan Luo & Pingsheng Hao. (2023) Successful Treatment of Recurrent Adult-Onset Still’s Disease with Tocilizumab: A Case Report and Literature Review. Clinical, Cosmetic and Investigational Dermatology 16, pages 3157-3163.
Read now
Read now
Paola Galozzi, Sara Bindoli, Andrea Doria & Paolo Sfriso. (2022) Progress in Biological Therapies for Adult-Onset Still’s Disease. Biologics: Targets and Therapy 16, pages 21-34.
Read now
Read now
Alessandro Tomelleri, Corrado Campochiaro, Giacomo De Luca, Nicola Farina, Giulio Cavalli & Lorenzo Dagna. (2021) Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease. Expert Opinion on Orphan Drugs 9:3, pages 77-86.
Read now
Read now
Ewa Więsik-Szewczyk, Anna Felis-Giemza, Mirosław Dziuk & Karina Jahnz-Różyk. (2020) Schnitzler Syndrome in a 27-Year-Old Man: Diagnostic and Therapeutic Dilemma in Adult Auto-Inflammatory Syndromes A Case Report and Literature Review. International Journal of General Medicine 13, pages 713-719.
Read now
Read now
Giulio Cavalli, Nicola Farina, Corrado Campochiaro, Elena Baldissera & Lorenzo Dagna. (2020) Current treatment options and safety considerations when treating adult-onset Still’s disease. Expert Opinion on Drug Safety 19:12, pages 1549-1558.
Read now
Read now
Paolo Sfriso, Sara Bindoli, Andrea Doria, Eugen Feist & Paola Galozzi. (2020) Canakinumab for the treatment of adult-onset Still’s disease. Expert Review of Clinical Immunology 16:2, pages 129-138.
Read now
Read now
Piero Ruscitti, Alessandro Conforti, Viktoriya Pavlych & Roberto Giacomelli. (2019) Inhibiting inflammatory cytokines in adult onset Still’s disease. Current trends and new therapeutic perspectives. Expert Opinion on Orphan Drugs 7:12, pages 547-554.
Read now
Read now
Dae Hyun Yoo. (2019) Biologics for the treatment of adult-onset still’s disease. Expert Opinion on Biological Therapy 19:11, pages 1173-1190.
Read now
Read now
Articles from other publishers (32)
Xiao-Kai Chi, Xiao-Ling Xu, Bang-Yao Chen, Jin Su & Yong-Zhong Du. (2023) Combining nanotechnology with monoclonal antibody drugs for rheumatoid arthritis treatments. Journal of Nanobiotechnology 21:1.
Crossref
Crossref
Kazuto Togitani, Fumiya Ogasawara, Yu Arakawa, Natsuki Sugimura, Ryohei Miyazaki & Kensuke Kojima. (2023) Psoas and Mediastinal Abscesses during Intravenous Tocilizumab Treatment in Multicentric Castleman Disease. Internal Medicine 62:3, pages 449-452.
Crossref
Crossref
Bruno Fautrel, Jacoby Patterson, Catherine Bowe, Mick Arber, Julie Glanville, Stuart Mealing, Viviam Canon-Garcia, Laura Fagerhed, Hilde Rabijns & Roberto Giacomelli. (2023) Systematic review on the use of biologics in adult-onset still's disease. Seminars in Arthritis and Rheumatism 58, pages 152139.
Crossref
Crossref
Sheng Li, Shuni Ying, Juan Bai, Yuqian Wang, Changyi Yang, Qingmiao Sun, Hong Fang & Jianjun Qiao. (2023) Clinical characteristics and outcome of elderly onset adult-onset Still's disease: A 10-year retrospective study. Journal of Translational Autoimmunity 6, pages 100196.
Crossref
Crossref
Luana Andreea Macovei, Alexandra Burlui, Ioana Bratoiu, Ciprian Rezus, Anca Cardoneanu, Patricia Richter, Andreea Szalontay & Elena Rezus. (2022) Adult-Onset Still’s Disease—A Complex Disease, a Challenging Treatment. International Journal of Molecular Sciences 23:21, pages 12810.
Crossref
Crossref
Juan Carlos Ruiz-Rodríguez, Luis Chiscano-Camón, Adolf Ruiz-Sanmartin, Clara Palmada, Ivan Bajaña, Gloria Iacoboni, Camilo Bonilla, Alejandra García-Roche, Erika Paola Plata-Menchaca, Carolina Maldonado, Marcos Pérez-Carrasco, Mónica Martinez-Gallo, Clara Franco-Jarava, Manuel Hernández-González & Ricard Ferrer. (2022) Case report: Cytokine hemoadsorption in a case of hemophagocytic lymphohistiocytosis secondary to extranodal NK/T-cell lymphoma. Frontiers in Medicine 9.
Crossref
Crossref
Bowen Xu, Jian Wang, Xiaoying Meng & Binghao Bao. (2022) Bibliometrics and Visual Analysis of Adult-onset Still Disease (1976–2020). Frontiers in Public Health 10.
Crossref
Crossref
Melissa R. Hines, Tatiana von Bahr Greenwood, Gernot Beutel, Karin Beutel, J. Allyson Hays, AnnaCarin Horne, Gritta Janka, Michael B. Jordan, Jan A. M. van Laar, Gunnar Lachmann, Kai Lehmberg, Rafal Machowicz, Päivi Miettunen, Paul La Rosée, Bita Shakoory, Matt S. Zinter & Jan-Inge Henter. (2021) Consensus-Based Guidelines for the Recognition, Diagnosis, and Management of Hemophagocytic Lymphohistiocytosis in Critically Ill Children and Adults. Critical Care Medicine 50:5, pages 860-872.
Crossref
Crossref
Kuo-Tung Tang, Chia-Wei Hsieh, Hsin-Hua Chen, Yi-Ming Chen, Shih-Hsin Chang, Po-Hao Huang, Joung-Liang Lan & Der-Yuan Chen. (2021) The effectiveness of tocilizumab in treating refractory adult-onset Still’s disease with dichotomous phenotypes: IL-18 is a potential predictor of therapeutic response. Clinical Rheumatology 41:2, pages 557-566.
Crossref
Crossref
Julián M. Cota-Arce, Jonhatan Cota, Marco A. De León-Nava, Alexia Hernández-Cáceres, Leopoldo I. Moncayo-Salazar, Fidel Valle-Alvarado, Vera L. Cordero-Moreno, Karen L. Bonfil-Solis, Jesús E. Bichara-Figueroa, José Hernández-Hernández & Luis Villela. (2021) Efficacy and safety of canakinumab in the treatment of adult-onset Still's disease: A systematic review. Seminars in Arthritis and Rheumatism 51:6, pages 1282-1290.
Crossref
Crossref
Dennis A. Eichenauer, Gunnar Lachmann & Paul La Rosée. (2021) Die hämophagozytische Lymphohistiozytose bei kritisch kranken PatientenHemophagocytic lymphohistiocytosis in critically ill patients. Wiener klinisches Magazin 24:6, pages 246-251.
Crossref
Crossref
Irene Sollano-Sancho, Beatriz Rubio-Cebrian, Maria Luisa de la Cruz & Blanca San-Jose-Montano. (2021) Successful treatment of interstitial pneumonitis with anakinra in a patient with adult-onset Still’s disease. European Journal of Hospital Pharmacy 28:6, pages 346-349.
Crossref
Crossref
Yuning Ma, Jianfen Meng, Jinchao Jia, Mengyan Wang, Jialin Teng, Dehao Zhu, Chengde Yang & Qiongyi Hu. (2021) Current and emerging biological therapy in adult-onset Still’s disease. Rheumatology 60:9, pages 3986-4000.
Crossref
Crossref
Po-Ku Chen & Der-Yuan Chen. (2021) An Update on the Pathogenic Role of Macrophages in Adult-Onset Still’s Disease and Its Implication in Clinical Manifestations and Novel Therapeutics. Journal of Immunology Research 2021, pages 1-11.
Crossref
Crossref
Ines Doko Vajdić, Goran Štimac, Ivan Pezelj, Matej Mustapić & Simeon Grazio. (2021) Psoas abscess during treatment with intravenous tocilizumab in a patient with rheumatoid arthritis: a case-based review. Rheumatology International 41:4, pages 819-825.
Crossref
Crossref
Seher Kır, Metin Özgen & Sezgin Zontul. (2020) Adult‐onset still’s disease and treatment results with tocilizumab. International Journal of Clinical Practice 75:3.
Crossref
Crossref
D. A. Eichenauer, G. Lachmann & P. La Rosée. (2021) Die hämophagozytische Lymphohistiozytose bei kritisch kranken PatientenHemophagocytic lymphohistiocytosis in critically ill patients. Medizinische Klinik - Intensivmedizin und Notfallmedizin 116:2, pages 129-134.
Crossref
Crossref
Zhong-Bin Han, Ju Wu, Jing Liu, He-Ming Li, Kai Guo & Tong Sun. (2021) Adult-onset Still's disease evolving with multiple organ failure and death: A case report and review of the literature. World Journal of Clinical Cases 9:4, pages 886-897.
Crossref
Crossref
Corrado Campochiaro, Nicola Farina, Alessandro Tomelleri, Giacomo De Luca, Elena Baldissera, Giulio Cavalli & Lorenzo Dagna. (2021) Drug retention rates of biological agents in adult onset Still's disease. Seminars in Arthritis and Rheumatism 51:1, pages 1-6.
Crossref
Crossref
Cornelia KnaakFriederike S. SchusterPeter NyvltClaudia SpiesInsa FeinkohlGernot BeutelThomas SchenkPaul La RoséeGritta JankaFrank M. BrunkhorstDidier KehGunnar Lachmann. (2020) Treatment and Mortality of Hemophagocytic Lymphohistiocytosis in Adult Critically Ill Patients: A Systematic Review With Pooled Analysis. Critical Care Medicine 48:11, pages e1137-e1146.
Crossref
Crossref
Roberto Ravasio, Roberto Giacomelli & Stefano Bianchi. (2020) Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease. Global & Regional Health Technology Assessment 7:1, pages 72-80.
Crossref
Crossref
Ayse Serap Karadag, Melek Aslan Kayıran, Torello Lotti & Uwe Wollina. (2020) Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days. Dermatologic Therapy 33:5.
Crossref
Crossref
Shivaraj Nagalli, Ashish Sharma, Nidhi Shankar Kikkeri & Nasef Sherif. (2020) A Case Report on Adult-Onset Still’s Disease Successfully Treated With Tocilizumab: A Brief Review on its Safety and Efficacy. Cureus.
Crossref
Crossref
Salvatore Bellinvia, Christopher J. Edwards, Matteo Schisano, Paolo Banfi, Matteo Fallico & Paolo Murabito. (2020) The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm?. Inflammation Research 69:8, pages 757-763.
Crossref
Crossref
Cornelia Knaak, Friederike S. Schuster, Claudia Spies, Gerald Vorderwülbecke, Peter Nyvlt, Thomas Schenk, Felix Balzer, Paul La Rosée, Gritta Janka, Frank M. Brunkhorst, Didier Keh & Gunnar Lachmann. (2020) Hemophagocytic Lymphohistiocytosis in Critically Ill Patients. Shock 53:6, pages 701-709.
Crossref
Crossref
Sheng Li, Siting Zheng, Shunli Tang, Yunlei Pan, Shan Zhang, Hong Fang & Jianjun Qiao. (2019) Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still’s Disease. Clinical Reviews in Allergy & Immunology 58:1, pages 71-81.
Crossref
Crossref
Sofia Ajeganova, Ann De Becker & Rik Schots. (2020) Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still’s disease: when dosage matters in overcoming secondary therapy resistance. Therapeutic Advances in Musculoskeletal Disease 12, pages 1759720X2097485.
Crossref
Crossref
François Vercruysse, Thomas Barnetche, Estibaliz Lazaro, Emilie Shipley, François Lifermann, Alexandre Balageas, Xavier Delbrel, Bruno Fautrel, Christophe Richez, Thierry Schaeverbeke & Marie-Elise Truchetet. (2019) Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Research & Therapy 21:1.
Crossref
Crossref
Jianjun Qiao, Yunlei Pan, Sheng Li, Shunli Tang, Siting Zheng, Dingxian Zhu, Chuanyin Sun & Hong Fang. (2019) Adult-Onset Still Disease Presenting With Dermatomyositis-Like Persistent Pruritic Lesions. The American Journal of Dermatopathology 41:11, pages 851-854.
Crossref
Crossref
Paul La Rosée, AnnaCarin HorneMelissa HinesTatiana von Bahr Greenwood, Rafal Machowicz, Nancy Berliner, Sebastian BirndtJuana Gil-HerreraMichael Girschikofsky, Michael B. Jordan, Ashish Kumar, Jan A. M. van LaarGunnar Lachmann, Kim E. Nichols, Athimalaipet V. Ramanan, Yini Wang, Zhao Wang, Gritta Janka & Jan-Inge Henter. (2019) Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133:23, pages 2465-2477.
Crossref
Crossref
Piero Ruscitti, Paola Cipriani, Vasiliki Liakouli, Giuliana Guggino, Francesco Carubbi, Onorina Berardicurti, Francesco Ciccia & Roberto Giacomelli. (2019) Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study. Medicine 98:15, pages e15123.
Crossref
Crossref
Katherine A. Lyseng-Williamson. (2018) Anakinra in Still’s disease: a profile of its use. Drugs & Therapy Perspectives 34:12, pages 543-553.
Crossref
Crossref